No. of Recommendations: 4
The explanation for Pfizer's sinking stock price seems to be fairly clear: over the last 30 days, earnings projections have been significantly reduced by a chorus of analysts. What is more, earnings growth over the next five years is now projected to be anemic, at best. For example, Yahoo, citing 18 analysts (at least for next year's net earnings) projects earnings growth for the next 5 Years (per annum) to be -5.45%. Other sources, more or less, agree. I can't find a consensus of earnings per share of more than $4 a share (per annum) for at least the next three years. Given this, Pfizer's present P/E ratio seems in the realm of fair value. The stock does however offer a generous and safe dividend.
On a risk reward basis Pfizer, given its current valuation/stock price, seems a fair bet given current conditions. But, a "table pounding idea"; I'm skeptical.